Literature DB >> 20464035

High mobility group box-1 and cardiovascular diseases.

Hua-Sheng Ding1, Jun Yang.   

Abstract

High mobility group box-1 (HMGB1) is a highly conserved, ubiquitous protein in the nuclei and cytoplasm of almost all cells. After binding to its receptor, HMGB1, which is derived from necrotic cells and activated macrophages/monocytes, functions as a critical mediator of inflammation and promotes tissue repair and regeneration. Many recent studies demonstrated that HMGB1 played a pivotal role in cardiovascular diseases, such as atherosclerosis, myocardial ischemia/reperfusion injury, heart failure, and myocardial infarction. In this review, we focus on HMGB1 and summarize the association of HMGB1 with cardiovascular diseases.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20464035

Source DB:  PubMed          Journal:  Saudi Med J        ISSN： 0379-5284            Impact factor:   1.484


  15 in total

1.  High mobility group box protein-1 correlates with microinflammatory state and nutritional status in continuous ambulatory peritoneal dialysis patients.

Authors:  Nan Zhu; Weijie Yuan; Yi Zhou; Jun Liu; Jinfang Bao; Jing Hao; Wen Miao
Journal:  J Artif Organs       Date:  2011-03-26       Impact factor: 1.731

2.  Effects of lower concentration thrombin on high-mobility group box 1 protein-mediated inflammatory responses.

Authors:  Jong-Sup Bae
Journal:  Inflammation       Date:  2012-06       Impact factor: 4.092

Review 3.  HMGB1 in health and disease.

Authors:  Rui Kang; Ruochan Chen; Qiuhong Zhang; Wen Hou; Sha Wu; Lizhi Cao; Jin Huang; Yan Yu; Xue-Gong Fan; Zhengwen Yan; Xiaofang Sun; Haichao Wang; Qingde Wang; Allan Tsung; Timothy R Billiar; Herbert J Zeh; Michael T Lotze; Daolin Tang
Journal:  Mol Aspects Med       Date:  2014-07-08

4.  HMGB1 attenuates cardiac remodelling in the failing heart via enhanced cardiac regeneration and miR-206-mediated inhibition of TIMP-3.

Authors:  Federica Limana; Grazia Esposito; Daniela D'Arcangelo; Anna Di Carlo; Sveva Romani; Guido Melillo; Antonella Mangoni; Chiara Bertolami; Giulio Pompilio; Antonia Germani; Maurizio C Capogrossi
Journal:  PLoS One       Date:  2011-06-22       Impact factor: 3.240

5.  Store-operated Ca2+ entry plays a role in HMGB1-induced vascular endothelial cell hyperpermeability.

Authors:  Mengchen Zou; Hangming Dong; Xiaojing Meng; Chunqing Cai; Chenzhong Li; Shaoxi Cai; Yaoming Xue
Journal:  PLoS One       Date:  2015-04-17       Impact factor: 3.240

6.  High mobility group box 1 protein attenuates myocardial ischemia reperfusion injury via inhibition of the p38 mitogen-activated protein kinase signaling pathway.

Authors:  Yan-Hong Zhou; Qian-Feng Han; Lan-Hua Wang; Tao Liu; Xiao-Yan Meng; Lei Wu; Tai Li; Yue-Ru Jiao; Heng-Chen Yao; De-Yong Zhang
Journal:  Exp Ther Med       Date:  2017-06-22       Impact factor: 2.447

7.  Fluvastatin attenuated ischemia/reperfusion-induced autophagy and apoptosis in cardiomyocytes through down-regulation HMGB1/TLR4 signaling pathway.

Authors:  Hua-Sheng Ding; Jun Yang; Jian Yang; Xin Guo; Yan-Hong Tang; Yan Huang; Zhen Chen; Zhi-Xing Fan; Cong-Xin Huang
Journal:  Mol Biol Rep       Date:  2021-05-25       Impact factor: 2.316

8.  Relationship between plasma high mobility group box-1 protein levels and clinical outcomes of aneurysmal subarachnoid hemorrhage.

Authors:  Xiang-Dong Zhu; Jing-Sen Chen; Feng Zhou; Qi-Chang Liu; Gao Chen; Jian-Min Zhang
Journal:  J Neuroinflammation       Date:  2012-08-11       Impact factor: 8.322

9.  Atorvastatin reduces serum HMGB1 levels in patients with hyperlipidemia.

Authors:  Daoqun Jin; Yongbo Wu; Lin Zhao; Jie Guo; Kai Zhang; Zhiqiang Chen
Journal:  Exp Ther Med       Date:  2012-10-01       Impact factor: 2.447

10.  Intravenous high mobility group box 1 upregulates the expression of HIF-1α in the myocardium via a protein kinase B-dependent pathway in rats following acute myocardial ischemia.

Authors:  Heng-Chen Yao; Min Zhou; Yan-Hong Zhou; Lan-Hua Wang; De-Yong Zhang; Qian-Feng Han; Tao Liu; Lei Wu; Ke-Li Tian; Mei Zhang
Journal:  Mol Med Rep       Date:  2015-12-07       Impact factor: 2.952
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.